Hepatitis C virus vaccine design: focus on the humoral immune response.

ABSTRACT: Despite the recent development of safe and highly effective direct-acting antivirals, hepatitis C virus (HCV) infection remains a significant health problem. In 2016, the World Health Organization set out to reduce the rate of new HCV infections by 90% by 2030. Still, global control of the virus does not seem to be achievable in the absence of an effective vaccine. Current approaches to the development of a vaccine against HCV include the production of recombinant proteins, synthetic peptides, DNA vaccines, virus-like particles, and viral vectors expressing various antigens. In this review, we focus on the development of vaccines targeting the humoral immune response against HCV based on the cumulative evidence supporting the important role of neutralizing antibodies in protection against

SUBMITTER: Sepulveda-Crespo D 

PROVIDER: S-EPMC7338099 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature